论文部分内容阅读
多药耐药（ＭＤＲ）现象是恶性肿瘤化疗失败的常见原因。人体内ＭＤＲ１表达的低水平、不均匀、变异性及广泛性，给ＭＤＲ１基因检测及解释带来困难。目前理想的检测方法是联合分析糖蛋白（Ｐｇｐ）水平（如ＩＨＣ）、ｍＲＮＡ（如ＰＴＰＣＲ或ｍＲＮＡ原位杂交）及Ｐｇｐ功能（药物或染料排出）的多参检验，同时应用合适的标准化系列细胞株作内参照。只有建立能被广泛接受且简单可靠的定性及定量检测ＭＤＲ１基因的方法，才能使作为肿瘤标记和治疗靶点的ＭＤＲ１基因研究应用于临床。
Multidrug resistance (MDR) is a common cause of chemotherapy failure in malignant tumors. The low level, inhomogeneity, variability and extensiveness of MDR1 expression in the human body make it difficult to detect and interpret the MDR1 gene. At present, the ideal detection method is a multi-parametric test combining glycoprotein (P gp) level (such as IHC), mRNA (such as PT PCR or mRNA in situ hybridization), and P gp function (drug or dye discharge). Appropriate standardized series of cell lines were used as internal controls. Only the establishment of a well-accepted and simple and reliable method for qualitative and quantitative detection of MDR1 gene can make the study of MDR1 gene as a tumor marker and therapeutic target applicable to the clinic.